Factors Influencing SARS-CoV-2 Vaccine Acceptance and Hesitancy in a Population-Based Sample in Italy
- PMID: 34200656
- PMCID: PMC8228124
- DOI: 10.3390/vaccines9060633
Factors Influencing SARS-CoV-2 Vaccine Acceptance and Hesitancy in a Population-Based Sample in Italy
Abstract
Vaccination against SARS-CoV-2 represents an effective and safe tool to protect the population against the disease; however, COVID-19 vaccine hesitancy could be a major barrier to achieving herd immunity. Despite the severity of the current pandemic, the population's intention to get vaccinated against COVID-19 is still not clear. The aim of this study was to evaluate the intention to get vaccinated against COVID-19 among a convenience sample of the general population resident in Italy and the factors associated with hesitancy and acceptance of the vaccine in the context of the current pandemic before the rolling out of COVID-19 vaccines. An anonymous online survey was diffused among a general adult population living in Italy. Participants aged 18 or older and living in Italy were considered eligible. Incomplete questionnaires were excluded. Overall, 7605 valid questionnaires were collected. Most of the participants (81.9%) were inclined to get vaccinated; male sex (OR 1.38, 95% CI 1.12-1.71), a high level of trust in institutions (OR 3.93, 95% CI 2.04-7.83), and personal beliefs about high safety of COVID-19 vaccines (OR 56.33, 95% CI 31.57-105.87) were found to be among the significant predictors of COVID-19 acceptance. These data could help design larger studies to address the problem of COVID-19 vaccine hesitancy in the current pandemic.
Keywords: COVID-19; SARS-CoV-2; survey; vaccine acceptance; vaccine hesitancy.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- World Health Organization Director-General’s Opening Remarks at the Media Briefing on COVID-19—11 March 2020. [(accessed on 18 April 2021)]; Available online: https://www.who.int/director-general/speeches/detail/who-director-genera....
-
- Dipartimento della Protezione Civile. [(accessed on 18 April 2021)]; Available online: https://opendatadpc.maps.arcgis.com/apps/dashboards/b0c68bce2cce478eaac8....
-
- Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous